Back to results
US 10,517,861 B2Granted
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AssigneeEisai R&D Management Co., Ltd.
InventorsYasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
Life of this patent
Estimating the term…
Abstract
Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
Claims15
A method of treating an endometrial cancer, comprising:
- determining that the concentration of Angiopoietin 2 (Ang2) protein is low, as compared to a control, in a biological sample obtained from a human subject that has an endometrial cancer, wherein the biological sample is a blood sample, a serum sample, or a plasma sample;
- and
- administering to the subject a therapeutically effective amount of lenvatinib or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.